Litigation Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)
✉ Email this page to a colleague
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-06-09 |
| Court | District Court, N.D. West Virginia | Date Terminated | 2024-03-18 |
| Cause | 35:271 Patent Infringement | Assigned To | John Preston Bailey |
| Jury Demand | None | Referred To | |
| Patents | 8,318,802; 8,598,227 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-06-09 | 1 | Complaint (NOT for attorney use) | of United States Patent No. 8,318,802 (“the ’802 patent”) and United States Patent No. 8,598,227 (“the…the ’227 patent”) (collectively, “the patents-in-suit”). This action arises under the Patent Laws of …(Attachments: # 1 Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Civil Cover …the ’802 patent, titled “Epoprostenol Formulation and Method of Making Thereof.” The ’802 patent was duly…the ’802 patent is attached as Exhibit A. 17. Actelion owns the ’227 patent, titled | External link to document |
| 2021-12-22 | 136 | Certificate of Service | Ph.D. Regarding on Indefinitetness of U.S. Patent Nos. 8,318,802 and 8,598,227). (O'Brien, William) (Entered…2020 18 March 2024 1:20-cv-00110 835 Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
| 2022-02-14 | 143 | Memorandum & Opinion | Actelion”), U.S. Patent Nos. 8,318,802 (the “’802 patent”) and 8,598,227 (the “’227 patent”) (collectively…CONSTRUCTION This patent infringement case involves two United States Patents owned by Actelion Pharmaceuticals… “It is a bedrock principle of patent law that the claims of a patent define the invention to which the…When construing patent claims, then, a court must consider the context of the entire patent, including both…unasserted claims. Id. at 1314. Because a patent will ordinarily use patent terms consistently, “the usage of | External link to document |
| 2023-11-21 | 197 | Memorandum | INTRODUCTION U.S. Patent Nos. 8,318,802 and 8,598,227 (“the patents-in-suit”) protect Actelion…Provisional Patent Application . . . filed 2006 . . . .” ’802 patent at 1:1–7. The ’802 and ’277 patents share…, slip op. at 9. The patent has an effective filing date of 2006: “[t]his patent application claims …..................................... 6 III. PATENT BACKGOUND .....................................…stability without adverse effects on patients. ’802 patent at 4:38-47.2 Actelion has maintained | External link to document |
| 2023-11-21 | 198 | terms of U.S. Patent Nos. 8,318,802 (“the ’802 patent”) and 8,598,227 (“the ’227 patent”) (collectively…collectively, “the patents” or “the patents-in-suit”) as a person of ordinary skill in the art (a “POSA”)…protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark…construction hearing offering expert testimony in a patent infringement case involving the use of bioreactors… I understand from counsel that the claims of a patent define the invention to which the patentee is | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
